Receipt of BNT162b2 KP.2 Vaccine and COVID-19 CVS MinuteClinic Visits in US Adults
Rudolph, A. E.; Khan, F. L.; Sun, X.; Lupton, L. L.; Puzniak, L. A.; Jodar, L.; McLaughlin, J. M.
Show abstract
Withdrawal statementThe authors have withdrawn this manuscript because when updating the data analysis, the authors discovered that a data source with vaccination information was incorrectly linked to in the initial dataset used for this analysis. As a result, some individuals that were dropped from our initial analysis due to missing vaccine information should not have been dropped and could therefore impact vaccine effectiveness estimates. We are committed to ensuring the highest standards in our research, and correcting these issues will require substantial revisions and additional analyses. Therefore, the authors do not wish this work to be cited as reference for the project. If you have any questions, please contact the corresponding author.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Single-dose mRNA vaccine effectiveness against SARS-CoV-2 in healthcare workers extending 16 weeks post-vaccination: a test-negative design from Quebec, Canada 93%
- Association of E484K and L452R spike protein mutations with SARS-CoV-2 infection in vaccinated persons---Maryland, January – May 2021 93%
- Single-dose mRNA vaccine effectiveness against SARS-CoV-2, including P.1 and B.1.1.7 variants: a test-negative design in adults 70 years and older in British Columbia, Canada 93%
Similar papers in this journal
- Effectiveness of the 2023-2024 Omicron XBB.1.5-containing mRNA COVID-19 vaccine (mRNA-1273.815) in preventing COVID-19-related hospitalizations and medical encounters among adults in the United States: An interim analysis 94%
- Effectiveness of the Coronavirus Disease 2019 (COVID-19) Bivalent Vaccine 93%
- Effectiveness of BNT162b2 XBB Vaccine against XBB and JN.1 Sub-lineages 92%
Similar papers in this journal
- 2024-2025 BNT162b2 COVID-19 vaccine effectiveness in non-immunocompromised adults: mid-season estimates from vaccine registries in two states linked to administrative claims 95%
- Safety Monitoring of Health Outcomes following Influenza Vaccination during the 2023-2024 Season among U.S. Medicare Beneficiaries Aged 65 Years and Older 93%
- Receipt of COVID-19 and seasonal influenza vaccines in California (USA) during the 2021-2022 influenza season 93%
Similar papers in this journal
- mRNA Vaccine Effectiveness against COVID-19 among Symptomatic Outpatients Aged ≥16 Years in the United States, February – May 2021 95%
- Recombinant adjuvanted zoster vaccine and reduced risk of COVID-19 diagnosis and hospitalization in older adults 95%
- Effectiveness of mRNA COVID-19 vaccines and hybrid immunity in preventing SARS-CoV-2 infection and symptomatic COVID-19 among adults in the United States 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.